“Xeltis has the potential to redefine heart valve replacement therapy”
21 . 02 . 2017

“Xeltis has the potential to redefine heart valve replacement therapy”

Leading cardiologist, Prof. Patrick Serruys introduced Xeltis’ revolutionary bioabsorbable heart valve to interventional cardiologists at the Cardiovascular Research Technologies (CRT) 2017 annual meeting today.

“Xeltis’ bioabsorbable technology has the potential to redefine heart valve replacement therapy,” stated Professor Serruys, Professor of Cardiology at Imperial College, London. “Through Endogenous Tissue Restoration, the new technology may help regenerate valves with long-lasting durability.”

CRT 17 took place in Washington D.C. 18-21 February, 2017. Attended by over 2,000 interventional and endovascular specialists, the meeting features cutting-edge data.

Go back